Close

Wells Fargo Downgrades Enzymotec (ENZY) to Market Perform

Go back to Wells Fargo Downgrades Enzymotec (ENZY) to Market Perform

Enzymotec (ENZY) Misses Q3 EPS by 4c; Trims FY16 Outlook; CEO Katz Resigns

November 16, 2016 7:33 AM EST

Enzymotec (NASDAQ: ENZY) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $11.4 million versus the consensus estimate of $13.3 million.

CEO Change:

Enzymotec also announced that Dr. Ariel Katz, the Companys President and Chief Executive Officer, will depart the Company by the end of May 2017, and the Board of Directors has initiated a... More